The temporal context of oral anticoagulation outcome in atrial fibrillation.
作者信息
Fender Anke C, Dobrev Dobromir
机构信息
Institute of Pharmacology, Medical Faculty, University Duisburg-Essen, Germany.
Department of Medicine and Research Center, Montreal Heart Institute and Université de Montréal, Montréal, Canada.
出版信息
Int J Cardiol Heart Vasc. 2022 May 13;40:101051. doi: 10.1016/j.ijcha.2022.101051. eCollection 2022 Jun.
Abstract
摘要
相似文献
1
The temporal context of oral anticoagulation outcome in atrial fibrillation.心房颤动口服抗凝治疗结局的时间背景
Int J Cardiol Heart Vasc. 2022 May 13;40:101051. doi: 10.1016/j.ijcha.2022.101051. eCollection 2022 Jun.
2
The Canadian Community Utilization of Stroke Prevention Study in Atrial Fibrillation in the Emergency Department (C-CUSP ED).加拿大社区在急诊科应用卒中预防治疗心房颤动研究（C-CUSP ED）。
Ann Emerg Med. 2019 Apr;73(4):382-392. doi: 10.1016/j.annemergmed.2018.09.001. Epub 2018 Oct 26.
3
Percutaneous left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation and contraindication for anticoagulation.经皮左心耳封堵术用于房颤且有抗凝禁忌证患者的卒中预防
Rev Neurol (Paris). 2015 May;171(5):426-32. doi: 10.1016/j.neurol.2014.11.009. Epub 2015 Apr 23.
4
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.氯吡格雷联合阿司匹林与口服抗凝药用于房颤患者预防血管事件的氯吡格雷与厄贝沙坦试验（ACTIVE W）：一项随机对照试验
Lancet. 2006 Jun 10;367(9526):1903-12. doi: 10.1016/S0140-6736(06)68845-4.
5
Ischemic stroke in patients with atrial fibrillation receiving oral anticoagulation.口服抗凝治疗的心房颤动患者的缺血性脑卒中。
J Neurol Sci. 2013 Nov 15;334(1-2):139-42. doi: 10.1016/j.jns.2013.08.013. Epub 2013 Aug 15.
6
Use of oral anticoagulation among stroke patients with atrial fibrillation in China: the ChinaQUEST (Quality evaluation of stroke care and treatment) registry study.中国心房颤动卒中患者的口服抗凝治疗应用：中国 QUEST（卒中护理和治疗质量评估）登记研究。
Int J Stroke. 2013 Apr;8(3):150-4. doi: 10.1111/j.1747-4949.2011.00716.x. Epub 2011 Dec 14.
7
[Anticoagulation with atrial fibrillation].[心房颤动的抗凝治疗]
Herzschrittmacherther Elektrophysiol. 2006 Jun;17(2):89-94. doi: 10.1007/s00399-006-0515-z.
8
Increasing rate of atrial fibrillation from 2003 to 2011 in patients with ischaemic stroke: results from 55,551 patients in a nationwide registry.2003年至2011年缺血性卒中患者心房颤动发生率上升：来自全国登记处55551例患者的结果。
Eur J Neurol. 2015 May;22(5):839-44. doi: 10.1111/ene.12671. Epub 2015 Feb 12.
9
Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.探索心房高率发作患者的口服抗凝治疗：心房高率发作患者非维生素K拮抗剂口服抗凝剂（NOAH-AFNET 6）试验的原理与设计
Am Heart J. 2017 Aug;190:12-18. doi: 10.1016/j.ahj.2017.04.015. Epub 2017 May 3.
10
'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.“真实世界”的心房颤动抗栓治疗：EORP-AF 初步调查。
Am J Med. 2014 Jun;127(6):519-29.e1. doi: 10.1016/j.amjmed.2013.12.022. Epub 2014 Jan 28.
引用本文的文献
1
Recent highlights from the on challenges for adequate stroke prevention in patients with atrial fibrillation.关于心房颤动患者充分预防卒中挑战的近期要点。
Int J Cardiol Heart Vasc. 2023 Aug 21;48:101259. doi: 10.1016/j.ijcha.2023.101259. eCollection 2023 Oct.
本文引用的文献
1
On-treatment follow-up in real-world studies of direct oral anticoagulants in atrial fibrillation: Association with treatment effects.心房颤动直接口服抗凝剂真实世界研究中的治疗期随访：与治疗效果的关联
Int J Cardiol Heart Vasc. 2022 Apr 4;40:101024. doi: 10.1016/j.ijcha.2022.101024. eCollection 2022 Jun.
2
Mental Health Conditions and Nonpersistence of Direct Oral Anticoagulant Use in Patients With Incident Atrial Fibrillation: A Nationwide Cohort Study.精神健康状况与新发心房颤动患者直接口服抗凝药物的不持续使用：一项全国性队列研究。
J Am Heart Assoc. 2022 Mar 15;11(6):e024119. doi: 10.1161/JAHA.121.024119. Epub 2022 Mar 1.
3
Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation.优化心房颤动患者非维生素K拮抗剂口服抗凝治疗的依从性和持续性
Eur Heart J Suppl. 2022 Feb 14;24(Suppl A):A42-A55. doi: 10.1093/eurheartj/suab152. eCollection 2022 Feb.
4
Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?非瓣膜性心房颤动患者从维生素 K 拮抗剂转换为直接口服抗凝剂：治疗范围达标时间是否会影响药物持续使用？
J Thromb Haemost. 2022 Feb;20(2):339-352. doi: 10.1111/jth.15592. Epub 2021 Nov 23.
5
Anticoagulation trends in adults aged 65 years and over with atrial fibrillation: a cohort study.65 岁及以上伴有心房颤动的成年人的抗凝趋势：一项队列研究。
Open Heart. 2021 Aug;8(2). doi: 10.1136/openhrt-2021-001737.
6
Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries.在五个西欧国家，房颤患者对非维生素 K 拮抗剂口服抗凝剂治疗的坚持和依从性。
Europace. 2021 Nov 8;23(11):1722-1730. doi: 10.1093/europace/euab091.
7
Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up.房颤抗凝治疗的持续性：来自GLORIA-AF III期1年随访的报告
J Clin Med. 2020 Jun 23;9(6):1969. doi: 10.3390/jcm9061969.
8
Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study.荷兰心房颤动口服抗凝治疗的持续性：一项监测研究。
Res Pract Thromb Haemost. 2019 Oct 24;4(1):141-153. doi: 10.1002/rth2.12261. eCollection 2020 Jan.
9
Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study.房颤患者直接口服抗凝剂的依从性和持久性：一项基于人群的研究。
Heart. 2020 Jan;106(2):119-126. doi: 10.1136/heartjnl-2019-315307. Epub 2019 Oct 10.
10
Evaluating utilization patterns of oral anticoagulants in routine care.评估常规治疗中口服抗凝剂的使用模式。
J Thromb Haemost. 2019 Jul;17(7):1033-1043. doi: 10.1111/jth.14467. Epub 2019 May 29.
Zotero 插件